The 267 references in paper Ya. Zverev F., A. Zharikov Yu., V. Brukhanov M., V. Lampatov V., Я. Зверев Ф., А. Жариков Ю., В. Брюханов М., В. Лампатов В. (2010) “МОДУЛЯТОРЫ ОКСАЛАТНОГО НЕФРОЛИТИАЗА. ИНГИБИТОРЫ КРИСТАЛЛИЗАЦИИ // MODULATORS OF OXALATE NEPHROLITHIASIS. INHIBITORS’ CRYSTALLIZATION” / spz:neicon:nefr:y:2010:i:1:p:29-49

1
Зверев ЯФ, Брюханов ВМ, Лампатов ВВ, Жариков АЮ. Современные представления о роли физико-химических факторов в патогенезе кальциевого нефролитиаза. Нефро­ логия 2009; 13 (1): 39-50
(check this in PDF content)
2
Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci; 2004; 9: 1450-1482
(check this in PDF content)
3
Kumar V, Lieske JC. Protein regulation of intrarenal crystallization. Curr Opin Nephrol Hypertens 2006; 15 (4): 374­ 380
(check this in PDF content)
4
Dent CE, Sutor DJ. Presence or absence of inhibitor of calcium-oxalate crystal growth in urine of normals and of stone- formers. Lancet 1971; 1: 776-778
(check this in PDF content)
5
Kumar V, Farell G, Lieske JC. Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells. J Urol 2003; 170 (1): 221-225
(check this in PDF content)
6
Tamm I, Horsfall FL. Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med 1950; 74: 108-114
(check this in PDF content)
7
Майданник ВГ, Дранник ГН. Белок Тамма-Хорсфал­ ла: патогенетическая роль и клиническое значение при уро­ логических и нефрологических заболеваниях. Урол и нефрол 1990; (5): 69-74
(check this in PDF content)
8
Kumar S, Muchmore S. Tamm-Horsfall protein- uromodulin (1950-1990). Kidney Int 1990; 37: 1395-1401
(check this in PDF content)
9
Gottschalk A. Carbohydrate residue of a urine mucoprotein inhibiting influenza virus haemagglutination. Nature 1952; 170: 662-663
(check this in PDF content)
10
Grant AM, Neuberger A. The development of a radioimmunoassay for the measurement of urinary Tamm- Horsfall glycoprotein in the presence of sodium dodecyl sulphate. Clin Sci 1973; 44: 163-179
(check this in PDF content)
11
Williams J, Marshall RD, van Halbeek H, Vliegenthart JF. Structural analysis of the carbohydrate moieties of human Tamm- Horsfall glycoprotein. Carbohydr Res 1984; 134 (1): 141-155
(check this in PDF content)
12
Muchmore AV, Decker JM. Uromodulin: a unique 85- kilodalton immunosuppressive glycoprotein isolated from urine of pregnant women. Science 1985; 229: 479-481
(check this in PDF content)
13
Peraldi MN. Tamm-Horsfall protein. Nephrologie 1992; 13 (1): 7-11
(check this in PDF content)
14
Devuyst O, Dahan K, Pirson Y Tamm-Horsfall protein or uromodulin: new ideas about an old molecule. Nephrol Dial Transplant 2005; 20 (7): 1290-1294
(check this in PDF content)
15
Serafini-Cessi F, Malagolini N, Cavallone D. Tamm- Horsfall glycop-rotein: biology and clinical relevance. Am J Kidney Dis 2003; 658-676
(check this in PDF content)
16
Gadella BM. The assembly of a zona pellucida binding protein complex in sperm. Reprod Domest Anim 2008; 43 (5): 12-19
(check this in PDF content)
17
Oelschlaeger T, Funfstuck R. Recurrent urinary tract infections in women. Virulence of pathogens and host reaction. Urologe A 2006; 45 (4): 412, 414416, 418-420
(check this in PDF content)
18
Pennica D, Kohr WJ, Kuang WJ et al. Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science 1987; 236: 83-88
(check this in PDF content)
19
Bachmann S, Koeppen-Hagemann I, Kriz W. Ultrastructural localization of Tamm-Horsfall glycoprotein (THP) in rat kidney as revealed by protein A-gold immunocytochemistry. Histochemistry 1985; 83 (6): 531-538
(check this in PDF content)
20
Bachmann S, Metzger R, Bunnemann B. Tamm-Horsfall protein-mRNA synthesis is localized to the thick ascending limb of Henle’s loop in rat kidney. Histochemistry 1990; 94 (5): 517-523
(check this in PDF content)
21
Malagolini N, Cavallone D, Serafini-Cessi F. Intracellular transport, cell-surface exposure and release of recombinant Tamm-Horsfall glycoprotein. Kidney Int 1997; 52 (5): 1340-1350
(check this in PDF content)
22
Pook MA, Jeremiah S, Scheinman SJ et al. Localization of the Tamm-Horsfall glycoprotein (uromodulin) gene to chromosome 16p12.3-16p13.11. Ann Hum Genet 1993; 57 (4): 285-290
(check this in PDF content)
23
Glauser A, Hochreiter W, Jaeger P, Hess B. Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 2000; 15: 1580-1587
(check this in PDF content)
24
Bichler KH, Kirchner Ch, Ideler V. Uromucoid excretion in normal individuals and stone formers. Br J Urol 1976; 47: 733-738
(check this in PDF content)
25
Samuell CT. Uromucoid excretion in normal subjects, calcium stone formers and in patients with chronic renal failure. Urol Res 1979; 7: 5-12
(check this in PDF content)
26
Thornley C, Dawnay A, Cattell WR. Human Tamm- Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. Clin Sci 1985; 68: 529-535
(check this in PDF content)
27
Scurr DS, Robertson WG. Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol 1986; 136: 128-131
(check this in PDF content)
28
Hess B, Zipperle L, Jaeger Ph. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 1993; 265: F784-779
(check this in PDF content)
29
Hebert SC. Bartter syndrome. Curr Opin Nephrol Hypertens 2003; 12: 527-532
(check this in PDF content)
30
Peters M, Ermert S, Jeck N et. al. Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2003; 64: 923­ 932
(check this in PDF content)
31
Зверев ЯФ, Брюханов ВМ, Лампатов ВВ. Заболева­ ния и синдромы, обусловленные генетическими нарушени­ ями почечного транспорта электролитов. Нефрология 2004; 8 (4): 11-24
(check this in PDF content)
32
Ying WZ, Sanders PW. Dietary salt regulates expression of Tamm-Horsfall glycoprotein in rats. Kidney Int 1998; 54 (4):1150-1156
(check this in PDF content)
33
Bachmann S, Dawnay AB, Bouby N, Bankir L. Tamm- Horsfall protein excretion during chronic alterations in urinary concentration and protein intake in the rat. Renal Physiol Biochem 1991; 14: 236-245
(check this in PDF content)
34
Bachmann S, Mutig K, Bates J et al. Renal effects of Tamm-Horsfall protein (uromodulin) deficiency in mice. Am J Physiol Renal Physiol 2005; 288: F559-F567
(check this in PDF content)
35
Rampoldi L, Caridi G, Santon D et al. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 2003; 15: 3369-3384
(check this in PDF content)
36
Schmitt R, Kahl T, Mutig K, Bachmann S. Selectively reduced expression of thick ascending limb Tamm-Horsfall protein in hypothyroid kidneys. Histochem Cell Biol 2004; 121 (4): 319-327
(check this in PDF content)
37
Fruhauf JH, Welker P, Mutig K et. al. Lipid raft association of essential proteins of the thick ascending limb. J Am Soc Nephrol 2003; 14: 561A
(check this in PDF content)
38
Kim GH, Ecelbarger CA, Mitchell C et. al. Vasopressin increases Na-K-2Cl cotransporter expression in thick ascending limb of Henle’s loop. Am J Physiol Renal Physiol 1999; 276: F96-F103
(check this in PDF content)
39
Grant AMS, Baker LRI, Neuberger A. Urinary Tamm- Horsfall glycoprotein in certain kidney diseases and its content in renal and bladder calculi. Clin Sci 1973; 44: 377-384
(check this in PDF content)
40
Bichler KH. Thirty-eight years of stone meetings in Europe. Urol Res 2006; 34 (2): 70-78
(check this in PDF content)
41
Knorle R, Schnierle P, Koch A et. al. Tamm-Horsfall Glycoprotein: Role in Inhibition and Promotion of Renal Calcium Oxalate Stone Formation Studied with Fourier-Transform Infrared Spectroscopy. Clin Chem 1994; 40 (9): 1739-1743
(check this in PDF content)
42
Khan SR. Interactions between stone-forming calcific crystals and macromolecules. Urol Int 1997; 59: 59-71
(check this in PDF content)
43
Doyle IR, Ryall RL, Marshall VR. Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon. Clin Chem 1991; 37: 1589-1594
(check this in PDF content)
44
Kulaksizoglu S, Sofikerim M, Cevik C. Impact of various modifiers on calcium oxalate crystallization. J Urol 2007; 14: 214­ 218
(check this in PDF content)
45
Hess B, Jordi S, Zipperle L et. al. Citrate determines calcium oxalate crystallization kinetics and crystal morphology- studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former. Nephrol Dial Transplant 2000; 15 (3): 366-374
(check this in PDF content)
46
Kumar V, Peca de la Vega L, Farell G, Lieske JC. Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int 2005; 68 (4): 1784-1792
(check this in PDF content)
47
Mo L, Huang HY Zhu XH et al. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 2004; 66 (3): 1159-1166
(check this in PDF content)
48
W iks^m B, Wieslander J. Excretion of Tamm-Horsfall urinary glycoprotein (uromucoid) in renal stone formers. In: Smith LH et al. eds. Urolithiasis, Clinical and Basic Research. Plenum Press, New York, 1981; 685-688
(check this in PDF content)
49
Erwin DT, Kok DJ, Alam J et al. Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton. Am J Kidney Dis 1994; 24 (6): 893-900
(check this in PDF content)
50
Romero MC, Nocera S, Nesse AB. Decreased Tamm- Horsfall protein in lithiasic patients. Clin Biochem 1997; 30 (1): 63-67
(check this in PDF content)
51
Hess B, Nakagawa Y, Parks JH, Coe FL. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 1991; 260 (4 Pt 2): F569-578
(check this in PDF content)
52
Boevй ER, Cao LC, De Bruijn WC et. al. Zeta potential distribution on calcium oxalate crystal and Tamm-Horsfall protein surface analyzed with Doppler electrophoretic light scattering. J Urol 1994; 152 (2 Pt 1): 531-536
(check this in PDF content)
53
Storey EL, Anderson GJ, Mack U et. al. Desialylated transferrin as a serological marker of chronic excessive alcohol ingestion. Lancet 1987; i: 1292-1294
(check this in PDF content)
54
Rademacher TW, Parekh RB, Dwek RA. Glycobiolor. Ann Rev Biochem 1988; 57: 785-838
(check this in PDF content)
55
Sumitra K, Pragasam V, Sakthivel R et al. Benefecial effect of vitamin E supplementation on the biochemical and kinetic properties of Tamm-Horsfall glycoprotein in hypertensive and hyperoxaluric patients. Nephrol Dial Transplant 2005; 20: 1407 -1415
(check this in PDF content)
56
Franzйn A, Heinegerd D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985; 232 (3): 715-724
(check this in PDF content)
57
Olberg A, Franzen A, Heidengard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986; 83 (23): 8819-8823
(check this in PDF content)
58
Helfrich MH, Nesbitt SA, Dorey EL, Horton MA. Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide- containing proteins, including the bone sialoproteins and fibronectin, a b3 integrin. J Bone Miner Res 1992; 7: 335-343
(check this in PDF content)
59
Butler WT. Structural and functional domains of osteopontin. Ann N YAcad Sci 1995; 760: 6-11
(check this in PDF content)
60
Hu DD, Lin EC, Kovach NL et al. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995; 270: 26232­ 26238
(check this in PDF content)
61
Liaw L, Skinner MP, Raines EW et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins: Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995; 95: 713­ 724
(check this in PDF content)
62
Weber GF, Ashkar A, Glimcher MJ, Cantor H. Receptor- ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-512
(check this in PDF content)
63
Sibalic V, Fan X, Loffing J, Wuthrich RP. Upregulated renal tubular CD44, hyaluronan, and osteopontin in kdkd mice with interstitial nephritis. Nephrol Dial Transplant 1997; 12: 1344-1353
(check this in PDF content)
64
Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11: 279-303
(check this in PDF content)
65
Verhulst A, Asselman M, Persy VP et al. Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding - into a nonadherent epithelium. J Am Soc Nephrol 2003; 14: 107-115
(check this in PDF content)
66
Yokosaki Y, Tanaka K, Higashikawa F et al. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol 2005; 24 (6): 418-427
(check this in PDF content)
67
Christensen B, Petersen TE, Sorensen ES. Post­ translational modification and proteolytic processing of urinary osteopontin. Biochem J 2008; 411: 53-61
(check this in PDF content)
68
Butler WT. The nature and significance of osteopontin. Connect Tissue Res 1989; 23: 123-136
(check this in PDF content)
69
Brown LF, Van de Water L, Papadopoulos-Sergiou A et al. Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol Biol Cell 1992; 2: 1169-1180
(check this in PDF content)
70
Giachelli C, Bae N, Lombardi D et al. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun 1991; 177: 867-873
(check this in PDF content)
71
Giachelli CM, Liaw L, Murry CE et al. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 1995; 760: 109-126
(check this in PDF content)
72
Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994; 145: 1450-1462
(check this in PDF content)
73
Sorensen S, Justesen SJ, Johnsen AH. Identification of a macromolecular crystal growth inhibitor in human urine as osteopontin. Urol Res 1995; 23: 327-334
(check this in PDF content)
74
Min W, Shiraga H, Chalko C et al. Quantitative studies of human urinary excretion of uropontin. Kidney Int 1998; 53: 189-193
(check this in PDF content)
75
Gericke A, Qin C, Spevak L et al. Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int 2005; 77 (1): 45-54
(check this in PDF content)
76
Nomura S, Wills AJ, Edwards DR et al. Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J Cell Biol 1988; 106: 441-450
(check this in PDF content)
77
Patarca R, Freeman GJ, Singh RP et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene: Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989; 170: 145-161
(check this in PDF content)
78
Shiraga H, Min W, VanDusen WJ et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: Another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 1992; 89: 426-430
(check this in PDF content)
79
Kohri K, Nomura S, Kitamura Y et al. Structure and expression the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 1993; 268 (15): 15180-15184
(check this in PDF content)
80
Denhardt DT, Guo X. Osteopontin: A protein with diverse functions. FASEB J 1993; 7: 1475-1482
(check this in PDF content)
81
Uede T, Katagiri Y lizuka J, Murakami M. Osteopontin, a coordinator of host defense system: A cytokine or an extracellular adhesive protein? Microbiol Immunol 1997; 41: 641-648
(check this in PDF content)
82
O’Brien EK, Garvin MR, Stewart DK et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994; 14: 1648-1656
(check this in PDF content)
83
Giachelli CM, Lombardi D, Johnson RJ et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353-358
(check this in PDF content)
84
Liaw L, Birk DE, Ballas CB et al. Altered wound healing in a mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101: 1468-1478
(check this in PDF content)
85
Scatena M, Almeida M, Chaisson ML et al. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-1093
(check this in PDF content)
86
Katagiri X Sleeman J, Fujii H et al. CD44 variants but not CD44s cooperate with 11-containing integrins to permit cells to bind to osteopontin independently of Arg-Gly-Asp acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59: 219-226
(check this in PDF content)
87
Ophascharoensuk V, Giachelli CM, Gorant K et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999; 56: 571-580
(check this in PDF content)
88
Sodek J, Batista Da Silva AP, Zohar R. Osteopontin and mucosal protection. J Dent Res 2006; 85 (5): 404-415
(check this in PDF content)
89
Denhardt DT, Noda M, O’Regan AW et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107: 1055-1061
(check this in PDF content)
90
Carlinfante G, Vassiliou D, Svensson O et al. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 2003; 20 (5): 437-444
(check this in PDF content)
91
Meller R, Stevens SL, Minami M et al. Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab 2005; 25 (2): 217-225
(check this in PDF content)
92
Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994; 300: 723-728
(check this in PDF content)
93
Hunter GK, Hauschka PV, Poole AR et al. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 1996; 317: 59-64
(check this in PDF content)
94
Rittling SR, Matsumo HN, McKee MD et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998; 13: 1101-1111
(check this in PDF content)
95
Boskey AL, Spevak L, Paschalis E et al. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 2002; 71: 145-154
(check this in PDF content)
96
Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy- induced bone resorption. Proc Natl Acad Sci USA 1999; 96: 156-160
(check this in PDF content)
97
Prince CW, Butler WT. 1,25-Dihydroxyvitamin D3 regulates the biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells. Collagen Rel Res 1987; 7: 305-313
(check this in PDF content)
98
Noda M, Rodan GA. Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J Biol Chem 1989; 108: 713-718
(check this in PDF content)
99
Noda M, Vogel RL, Craig AM et al. Identification of a DNA sequence responsible for binding of the 1,25- dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proc Natl Acad Sci USA 1990; 87: 9995-9999
(check this in PDF content)
100
Chang PL, Prince CW. 1 Alpha, 25-dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. Cancer Res 1994; 51: 2144-2150
(check this in PDF content)
101
Ihara H, Denhardt DT, Furuya K et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 2001; 276: 13065-13071
(check this in PDF content)
102
Niskanen LK, Suhonen M, Siitonen O et al. Aortic and lower limb artery calcification in type II (non-insulin-dependent) diabetic patients and non-diabetic control subjects: a five year follow-up study. Atherosclerosis 1990; 84: 61-71
(check this in PDF content)
103
Locker TH, Schwartz RS, Cotta CW, Hickman JR. Fluoroscopic coronary artery calcification and associated coronary disease in asymptomatic young men. J Am Coll Cardiol 1992; 19: 1167-1172
(check this in PDF content)
104
Puentes G, Detrano R, Tang W et al. Estimation of coronary calcium mass using electron beam computed tomography: a promising approach for predicting coronary events? Circulation 1995; 92: I313
(check this in PDF content)
105
Deneke T, Langner K, Gewe PH et al. Ossification in atherosclerotic carotid arteries. Z Kardiol 2001; 90 (Suppl 3): III/106-III/115
(check this in PDF content)
106
Olson JC, Edmundowicz D, Becker DJ et al. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000; 49: 1571-1578
(check this in PDF content)
107
Hirota S, Imakita M, Kohri K et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993; 143: 1003-1008
(check this in PDF content)
108
Ikeda T, Shirasawa T, Esaki Y et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993; 92: 2814­ 2820
(check this in PDF content)
109
Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994; 93: 2393­ 2402
(check this in PDF content)
110
O’Brien KD, Kuusisto J, Reichenbach DD et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995; 92: 2163-2168
(check this in PDF content)
111
Srivatsa SS, Harrity PJ, Maercklein PB et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest 1997;99: 996-1009
(check this in PDF content)
112
Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178
(check this in PDF content)
113
Chen J, Singh K, Mukherjee BB, Sodek J. Developmental expression of osteopontin (OPN) mRNA in rat tissues: Evidence for a role for OPN in bone formation and resorption. Matrix 1993; 13: 113-123
(check this in PDF content)
114
Madsen KM, Zhang L., Abu Shamat AR et al. Ultrastructural localization of osteopontin in the kidney: Induction by lipopolysaccharide. J Am Soc Nephrol 1997; 8: 1043-1053
(check this in PDF content)
115
Rogers SA, Padanilam BJ, Hruska KA et al. Metanephric osteopontin regulates nephrogenesis in vitro. Am J Physiol 1997; 272: F469-F476
(check this in PDF content)
116
Giachelli CM, Pichler R, Lombardi D et al. Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994; 45: 515-524
(check this in PDF content)
117
Pichler RH, Giachelli CM, Lombardi D et al. Tubulointerstitial disease in glomerulonephritis: Potential role of osteopontin (uropontin). Am J Pathol 1994; 144: 915-926
(check this in PDF content)
118
Pichler RH, Franceschini N, Young BA et al. Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186-1196
(check this in PDF content)
119
Magil AB, Pichler RH, Johnson RJ. Osteopontin in chronic puromycin aminonucleoside nephrosis. J Am Soc Nephrol 1997; 18: 1383-1390
(check this in PDF content)
120
Lopez CA, Hoyer JR, Wilson PD et al. Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest 1993; 69: 355-363
(check this in PDF content)
121
Kleinman JG, Beshensky A, Worcester EM, Brown D. Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int 1995; 47: 1585-1596
(check this in PDF content)
122
Hudkins KL, Giachelli CM, Cui Y et al. Osteopontin expression in fetal and mature human kidney. J Am Soc Nephrol 1999; 10: 444-457
(check this in PDF content)
123
Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL. The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 1992; 7: 1029-1036
(check this in PDF content)
124
Hoyer JP, Otvos LJr, Urge L. Osteopontin in urinary stone formation. Ann N YAcad Sci 1995; 760: 257-265
(check this in PDF content)
125
Worcester EM, Beshensky AM. Osteopontin inhibits nucleation of calcium oxalate crystals. Ann N YAcad Sci 1995; 760: 375-377
(check this in PDF content)
126
Wesson JA, Worcester EM, Weissner JH et al. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 1998; 53: 952-957
(check this in PDF content)
127
Umekawa T. Structural characteristics of osteopontin for calcium oxalate crystal. Nippon Hinyokika Gakkai Zasshi 1999; 90 (3): 436-444
(check this in PDF content)
128
Asplin JR, Arsenault D, Parks JH et al. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int 1998; 53: 194-199
(check this in PDF content)
129
Lieske JC, Leonard R, Toback FG. Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol 1995; 268: F604-F612
(check this in PDF content)
130
Lieske JC, Hammes MS, Hoyer JR, Toback FG. Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals. Kidney Int 1997; 51: 679-686
(check this in PDF content)
131
Gokhale JA, Glenton PA, Khan SR. Localization of Tamm-Horsfall peotein and osteopontin in a rat nephrolithiasis model. Nephron 1996; 73: 456-461
(check this in PDF content)
132
Jiang XJ, Feng T, Chang LS et al. Expression of osteopontin mRNA in normal and stone-forming rat kidney. Urol Res 1998; 26: 389-394
(check this in PDF content)
133
Yagisawa T, Chandhoke S, Fan J, Lucia S. Renal osteopontin expression in experimental urolithiasis. J Endourol 1998; 12: 171-176
(check this in PDF content)
134
Yasui T, Fujita K, Sasaki S et al. Expression of bone matrix proteins in urolithiasis model rats. Urol Res 1999; 27: 255-261
(check this in PDF content)
135
Beshensky AM, Wesson JA, Kleinman JG et al. Renoprotective modulation of calcium oxalate crystal structure by osteopontin in vivo. J Am Soc Nephrol 2000; 11: 558A
(check this in PDF content)
136
Mazzali M, Kipari T, Ophascharoensuk V et al. Osteopontin - A molecule for all seasons. QJM 2002; 95 (1): 3-13
(check this in PDF content)
137
Wesson JA, Johnson RJ, Mazzali M et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 2003; 14: 139-147
(check this in PDF content)
138
Mo L, Liaw L, Evan AP et al. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol 2007; 293: F1935- F1943
(check this in PDF content)
139
Yasui T, Fujita K, Hayashi Y et al. Quantification of osteopontin in the urine of healthy and stone-forming men. Urol Res 1999; 27: 225-230
(check this in PDF content)
140
Nishio S, Hatanaka M, Takeda H et al. Calcium phosphate crystal-associated proteins: alpha2-HS- glycoprotein, prothrombin F1, and osteopontin. Mol Urol 2000; 4: 383-390
(check this in PDF content)
141
Huang HS, Ma MC, Chen CF, Chen J. Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 2003; 62 (6): 1123-1128
(check this in PDF content)
142
Tsuji H, Tohru U, Hirotsugu U et al. Urinary concentration of osteopontin and association with urinary supersaturation and crystal formation. Int J Urol 2007; 14 (7): 630-634
(check this in PDF content)
143
Bautista DS, Denstedt J, Chambers AF, Harris JF. Low- molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem 1996; 61: 402-409
(check this in PDF content)
144
Hedgepeth RC, Yang L, Resnick MI, Marengo SR. Expression of proteins that inhibit calcium oxalate crystallization in vitro in the urine of normal and stone-forming individuals. Am J Kidney Dis 2001; 37: 104-112
(check this in PDF content)
145
Kleinman LG, Wesson JA, Hughes J. Osteopontin and calcium stone formation. Nephron Physiol 2004; 98: 43-47
(check this in PDF content)
146
Yamate T, Tsuji H, Amasaki N et al. Analysis of osteopontin DNA in patients with urolithiasis. Urol Res 2000; 28: 159-166
(check this in PDF content)
147
Gao B, Yasui T, Okada A et al. A polymorphism of the osteopontin gene is related to urinary calcium stones. J Urol 2005; 174: 1472-1476
(check this in PDF content)
148
Christensen B, Kazanecki CC, Petersen TE et al. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 2007; 282 (27): 19463-19472
(check this in PDF content)
149
Addadi L., Weiner S. Interactions between acidic proteins and crystals: Stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 1985; 82: 4110-4114
(check this in PDF content)
150
Wesson JA, Worcester E. Formation of hydrated calcium oxalate in the presence of poly-L-aspartic acid. Scanning Microsc 1996; 10: 415-424
(check this in PDF content)
151
Beshensky AM, Wesson JA, Worcester EM et al. Effects of urinary macromolecules on hydroxyapatite crystal formation. J Am Soc Nephrol 2001; 12: 2108-2116
(check this in PDF content)
152
Jung T, Sheng X, Choi CK et al. Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy. Langmuir 2004; 20: 8587-8596
(check this in PDF content)
153
Taller A, Grohe B, Rogers KA et al. Specific adsorption of osteopontin and synthetic polypeptides to calcium oxalate monohydrate crystals. Biophys J 2007; 93 (5): 1768-1777
(check this in PDF content)
154
Kohri K, Suzuki Y Yoshida K et al. Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin. Biochem Biophys Res Commun 1992; 184: 859-864
(check this in PDF content)
155
Yamate T, Kohri K, Umekawa T et al. The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells. Eur Urol 1996; 30: 388-393
(check this in PDF content)
156
Yamate T, Kohri K, Umekawa T et al. Interaction between osteopontin on Madin-Darby canine kidney cell membrane and calcium oxalate crystal. Urol Res 1999; 62: 81­ 86
(check this in PDF content)
157
Konya E, Umekawa T, Iguchi M, Kurita T. The role of osteopontin on calcium oxalate crystal formation. Eur Urol 2003; 43 (5): 564-571
(check this in PDF content)
158
Yasui T, Fujita K, Asai K, Kohri K. Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells. Int J Urol 2002; 9 (2): 100-108
(check this in PDF content)
159
Okada A, Nomura S, Saeki Y et al. Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney. J Bone Miner Res 2008; 23 (10): 1629-1637
(check this in PDF content)
160
Sorensen ES, Hojrup P, Petersen TE. Posttranslational modifications of bovine osteopontin: identification of twenty- eight phosphorylation and three O-glycosylation sites. Protein Sci 1995; 4: 2040-2049
(check this in PDF content)
161
Christensen B, Nielsen MS, Haselmann KF et al. Post- translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylated and five O-glycosylation sites and their biological implications. Biochem J 2005; 390: 285- 292
(check this in PDF content)
162
Keykhosravani M, Doherty-Kirby A, Zhang C et al. Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry 2005; 44: 6990- 7003
(check this in PDF content)
163
Boskey AL, Maresca M, Ullrich W et al. Osteopontin- hydroxyapatite interactions in vitro: Inhibition of hydroxyapatite formation and growth in gelatin-gel. Bone Miner 1993; 22: 147­ 159
(check this in PDF content)
164
Boskey AL. Osteopontin and related phosphorylated sialoproteins: effects on mineralization. Ann N YAcad Sci 1995; 760: 249- 256
(check this in PDF content)
165
Goldberg HA, Warner KJ, Li MC, Hunter GK. Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect Tissue Res 2001; 42: 25- 37
(check this in PDF content)
166
Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 2001; 60: 77- 82
(check this in PDF content)
167
Steitz SA, Speer MY, McKee MD et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002; 161 (6): 2035- 2046
(check this in PDF content)
168
Chen X Bal BS, Gorski JP. Calcium and collagen binding properties of osteopontin, and bone acidic glycoprotein-75 from bone. J Biol Chem 1992; 276: 24871- 24878
(check this in PDF content)
169
Coe FL, Boyce WH, Friedman GD et al. Prevention and treatment of kidney stones. J Urol 1989; 141: 804- 808
(check this in PDF content)
170
Sheng X, Ward MD, Wesson JA. Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation. J Am Soc Nephrol 2005; 16 (7): 1904- 1908
(check this in PDF content)
171
Ryall RL, Chauvet MC, Grover PK. Intracrystalline proteins and urolithiasis: a comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals. BJU International 2005; 96 (4): 654- 663
(check this in PDF content)
172
Falini G, Albeck S, Weiner S, Addadi L. Control of aragonite or calcite polymorphism by mollusk shell macromolecules. Science 1996; 271: 67- 69
(check this in PDF content)
173
Жариков АЮ, Зверев ЯФ, Брюханов ВМ, Лампа- тов ВВ. Современные представления о модуляторах окса­ латного нефролитиаза. I. Стимуляторы камнеобразования. Нефрология 2009; 13 (1): 56-72
(check this in PDF content)
174
Tomazie BB, Nancollas GH. The kinetics of dissolution of calcium oxalate hydrates II. The dihydrate. Invest Urol 1980; 18: 97-101
(check this in PDF content)
175
Lepage L, Tawashi R. Growth and characterization of calcium oxalate dihydrate crystals (weddellite). J Pharm Sci 1982; 71: 1059-1062
(check this in PDF content)
176
Wiessner JH, Mandel GS, Mandel NS. Membrane interactions with calcium oxalate crystals: variation in haemolytic potentials with crystal morphology. J Urol 1986; 135: 835-839
(check this in PDF content)
177
Wiessner JH, Hung LY, Mandel NS. Crystal attachment to injured renal collecting duct cells. Influence of urine proteins and pH. Kidney Int 2003; 63: 1313-1320
(check this in PDF content)
178
Ryall RL, Fleming DE, Grover PK et al. The hole truth. Intracrystalline proteins and calcium oxalate kidney stones. Mol Urol 2000; 4: 391-402
(check this in PDF content)
179
Ryall RL, Fleming DE, Doyle IR et al. Intracrystalline proteins and the hidden ultrastructure of calcium oxalate urinary crystals: Implications for kidney stone formation. J Struct Biol 2001; 134: 5-14
(check this in PDF content)
180
Fleming DE, van Riessen A, Chauvet MC et al. Intracrystalline proteins and urolithiasis: a synchrotron X-ray diffraction study of calcium oxalate monohydrate. J Bone Min Res 2003; 18: 1282-1291
(check this in PDF content)
181
Canales BK, Anderson L, Higgins L et al. Second prize: Comprehensive proteomic analysis of human calcium oxalate monohydrate kidney stone matrix. J Endourol 2008; 22 (6): 1161­ 1167
(check this in PDF content)
182
Merchant ML, Cummins TD, Wilkey DW et al. Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation. Am J Physiol Renal Physiol 2008; 295: F1254-F1258
(check this in PDF content)
183
Hoyer JR. Uropontin in urinary calcium stone formation. Miner Electrolyte Metab 1995; 20: 385-392
(check this in PDF content)
184
Atmani F, Opalko FJ, Khan SR. Association of urinary macromolecules with calcium oxalate crystals induced in vitro in normal human and rat urine. Urol Res 1996; 24: 45-50
(check this in PDF content)
185
Webber D, Rodgers AL, Sturrock ED. Selective inclusion of proteins into urinary calcium oxalate crystals: comparison between stone-prone and stone-free population groups. J Cryst Growth 2003; 259: 179-189
(check this in PDF content)
186
Chauvet MC, Ryall RL. Intracrystalline proteins and calcium oxalate crystal degradation in MDCK II cells. J Struct Biol 2005; 151: 12-17
(check this in PDF content)
187
Grover PK, Thurgood LA, Fleming DE et al. Intracrystalline urinary proteins facilitate degradation and dissolution of calcium oxalate crystals in cultured renal cells. Am J Physiol Renal Physiol 2008; 294: F355-F361
(check this in PDF content)
188
Le Hir M, Dubach UC, Schmidt U. Quantitative distribution of lysosomal hydrolases in the rat nephron. Histochemistry 1979; 63: 245-251
(check this in PDF content)
189
Khan SR, Shevock PN, Hackett RL. Urinary enzymes and calcium oxalate urolithiasis. J Urol 1989; 142: 846-849
(check this in PDF content)
190
Singh AK. Presence of lysosomal enzymes in the normal glomerular basement membrane matrix. Histochem J 1993; 25: 562-568
(check this in PDF content)
191
Kudo S, Miyamoto G, Kawano K. Proteases involved in the metabolic degradation of human interleukin-11 by rat kidney lysosomes. J Interferon Cytokine Res 1999; 19: 361-367
(check this in PDF content)
192
Bruijn WC, Boeve ER, van Run PR et al. Etiology of experimental calcium oxalate monohydrate nephrolithiasis in rats. Scanning Micr Int 1994; 8: 541-550
(check this in PDF content)
193
Water R, Nordermeer C, van der Kwast TH et al. Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis 1999; 33: 761-771
(check this in PDF content)
194
Water R, Nordemeer C, Houtsmuller AS et al. Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis 2000; 36: 615-625
(check this in PDF content)
195
Khan SR, Byer KJ, Thamilselvan S et al. Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells. J Am Soc Nephrol 1999; 10: S457-S463
(check this in PDF content)
196
Umekawa T, Chegini N, Khan SR. Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cell in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 2003; 18: 664-669
(check this in PDF content)
197
Khan SR, Shevock PN, Hackett RL. Acute hyperoxaluria, renal injury and calcium oxalate urolithiasis. J Urol 1992; 147: 226-230
(check this in PDF content)
198
Lieske JC, Deganello S, Toback GF. Cell-crystal interactions and kidney stone formation. Nephron 1999; 81 (Suppl 1): 8-17
(check this in PDF content)
199
Тиктинский ОЛ, Александров ВП. Мочекаменная болезнь. СПб: Питер, 2000; 29-30
(check this in PDF content)
200
Steinbuch M, Loeb J. Isolation of an a2-globulin from human plasma. Nature 1961; 192: 1196
(check this in PDF content)
201
Heide K, Heimburger N, Haupt H. An inter-a-trypsin inhibitor of human serum. Clin Chim Acta 1965; II: 82-85
(check this in PDF content)
202
Fries E, Kaczmarczyk A. Inter-a-inhibitor, hyaluronan and inflammation. Acta Biochim Pol 2003; 50 (3): 735-742
(check this in PDF content)
203
Chen L, Mao SJT, Larsen WJ. Identification of a factor in fetal bovine serum that stabilizes the cumules extracellular matrix, a role for member of the inter-alpha-inhibitor family. J Biol Chem 1992; 267: 12380-12386
(check this in PDF content)
204
Balduyck M, Laroui S, Mizon C, Mizon J. A proteoglycan related to the urinary trypsin inhibitor. Biol Chem Hoppe-Seyler 1989; 370: 331-336
(check this in PDF content)
205
Enghild JJ, Thogersen IB, Pizzo SV, Salvesen G. Analysis of inter-alpha-trypsin inhibitor and a novel trypsin inhibitor, pre-alpha-trypsin inhibitor, from human plasma: Polypeptide chain stoichiometry and assembly by glycan. J Biol Chem 1989; 264: 15975-15981
(check this in PDF content)
206
Malki N, Balduyck M, Maes P et al. The heavy chains of human plasma inter-alpha-trypsin inhibitor: Their isolation, their identification by electrophoresis and partial sequencing. Biol Chem Hoppe-Seyler 1992; 373: 1009-1018
(check this in PDF content)
207
Rouet P, Raguenez G, Tronche F et al. A potent enhancer made of clustered liver specific elements in the transcription control sequences of human alpha1-microglobulin/bikunin gene. J Biol Chem 1992; 267: 20765-20773
(check this in PDF content)
208
Hochstrasser K, Bretzel G, Feuth H et al. The intern- trypsin inhibitor as precursor of the acid-stable protease inhibitors in human serum and urine. Hoppe-Seyler’s Z Physiol Chem 1976; 357: 153-162
(check this in PDF content)
209
Dietl T, Dobrinski W, Hochstrasser K. Human intern- trypsin inhibitor: Limited proteolysis by trypsin, plasmin, kallikrein, and granulocytic elastase and inhibitory properties of the cleavage products. Hoppe-Seyler’s Z Physiol Chem 1979; 360: 1313-1318
(check this in PDF content)
210
Potempa J, Kwon K, Chawla R, Travis J. Inter-a-trypsin inhibitor: Inhibition spectrum of native and derived forms. J Biol Chem 1989; 264: 15109-15114
(check this in PDF content)
211
Salier JP. a-trypsin inhibitor: Emergence of a family within the Kunitz-type protease inhibitor superfamily. Trends Biochem Sci 1990; 15: 435-439
(check this in PDF content)
212
Xu Y Carr PD, Guss JM, Ollis DL. The crystal structure of bikunin from inter-alpha-inhibitor complex: a serine protease inhibitor with two Kunitz domains. J Mol Biol 1998; 276 (5): 955-966
(check this in PDF content)
213
Freis E, Blom AM. Bikunin - not just a plasma proteinase inhibitors. Int J Biochem Cell Biol 2000; 32 (2): 125­ 137
(check this in PDF content)
214
Pugia MJ, Valdes RJr, Jortani SA. Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement. Adv Clin Chem 2007; 44: 223-245
(check this in PDF content)
215
Wachter E, Hochstrasser K. Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-a-trypsin inhibitor, lY: the amino acid sequence of the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe-Seyler’s Z Physiol Chem 1981; 362: 1351-1355
(check this in PDF content)
216
Kanayama N, El Maradney E, Halim A et al. Urinary trypsin inhibitor prevents uterine muscle contraction by inhibition of Ca++ influx. Am J Obstet Gynecol 1995; 173: 192­ 199
(check this in PDF content)
217
Kanayama N, Halim A, Maehara K et al. Kunitz-type trypsin inhibitor prevents LPS-induced increase of cytosolic free Ca2+ in human neutrophils and HUVEC cells. Biochem Biophys Res Commun 1995; 207: 324-330
(check this in PDF content)
218
Maehara K, Kanayama N, Halim A et al. Down- regulation of interleukin-8 gene expression in HL60 cell line by human Kunitz-type trypsin inhibitor. Biochem Biophys Res Commun 1995; 206: 927-934
(check this in PDF content)
219
Zhuo L, Salustri A, Kimata K. A physiological function of serum proteoglycan bikunin: the chondroitin sulfate moiety plays a central role. Glycoconj J 2002; 19 (4-5): 241-247
(check this in PDF content)
220
Atmani F, Lacour B, Drueke T, Daudon M. Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization. Urol Res 1993; 21: 61-66
(check this in PDF content)
221
Bratt T, Olsson H, Sjoberg EM et al. Cleavage of the a1-microglobulin-bikunin precursor is localized to the Golgi apparatus of rat liver cells. Biochem Biophys Acta 1993; 1157: 147-154
(check this in PDF content)
222
Atmani F, Khan SR. Characterization of uronic-acid- rich inhibitor of calcium oxalate crystallization isolated from rat urine. Urol Res 1995; 23: 95-101
(check this in PDF content)
223
Tang Y Grover PK, Moritz RL et al. Is nephrocalcin related to the urinary derivative (bikunin) of inter-alpha-trypsin inhibitor? Br J Urol 1995; 75: 425-430
(check this in PDF content)
224
Atmani F, Lacour B, Jungers P et al. Molecular characteristics of uronic-acid-rich protein, a strong inhibitor of calcium oxalate crystallization in vitro. Biochem Biophys Res Commun 1993; 191: 1158-1165
(check this in PDF content)
225
Atmani F, Lacour B, Jungers P et al. Reduced inhibitory activity of uronic-acid-rich protein in urine of stone formers. 1994; 22: 257-260
(check this in PDF content)
226
Sorensen S, Hansen K, Bak S, Justesen SJ. An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res 1990; 18: 373-379
(check this in PDF content)
227
Atmani F, Mizon J, Khan SR. Identification of uronic- acid-rich protein as urinary bikunin the light chain of inter-a- inhibitor. Eur J Biochem 1996; 236: 984-990
(check this in PDF content)
228
Iida S, Peck AB, Johnson-Tardieu J et al. Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. J Am Soc Nephrol 1999; 10: 986-996
(check this in PDF content)
229
Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 2004; 8 (2): 75-88
(check this in PDF content)
230
Khan SR. Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 2006; 34 (2): 86-91
(check this in PDF content)
231
Grewal JC, Tsai JY Khan SR. Oxalate-inducible AMBP gene and its regulatory mechanism in renal tubular epithelial cells. Biochem J 2005; 387 (Pt 3): 609-616
(check this in PDF content)
232
Iida S, Johnson-Tardieu J, Glenton P et al. Molecular detection of bikunin in normal and oxalate-exposed kidneys and renal epithelial cells. J Am Soc Nephrol 1997; 8: 563A
(check this in PDF content)
233
Atmani F, Glenton PA, Khan SR. Role of inter-alpha- inhibitor and its related proteins in experimentally induced calcium oxalate urolithiasis. Localization of proteins and expression of bikunin gene in the rat kidney. Urol Res 1999; 27 (1): 63-67
(check this in PDF content)
234
Moriyama MT, Glenton PA, Khan SR. Expression of inter-alpha-inhibitor related proteins in kidneys and urine of hyperoxaluric rats. J Urol 2001; 165 (5): 1687-1692
(check this in PDF content)
235
Okuyama M, Yamaguchi S, Yachiku S. Identification of bikunin isolated from human urine inhibits calcium oxalate crystal growth and its localization in the kidneys. Int J Urol 2003; 10 (10): 530-535
(check this in PDF content)
236
Atmani F, Mizon J, Khan SR. Inter-a-inhibitor: a protein family involved in the inhibition of calcium oxalate crystallization. Scanning Microsc 1996; 10: 425-433
(check this in PDF content)
237
Atmani F, Khan SR. Inter-a-inhibitor, another serum protein with potential involvement in calcium oxalate nephrolithiasis. J Am Soc Nephrol 1996; 7: 1798A
(check this in PDF content)
238
Ebisuno S, Nishihata M, Inagaki T et al. Bikunin prevents adhesion of calcium oxalate crystal to renal tubular cells in human urine. J Am Soc Nephrol 1999; 10 (Suppl 14): S436-S440
(check this in PDF content)
239
Mйdйtognon-Benissan J, Tardivel S, Hennequin C et al. Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers. Urol Res 1999; 27 (1): 69-75
(check this in PDF content)
240
Atmani F, Khan SR. Role of urinary bikunin in the inhibition of calcium oxalate crystallization. J Am Soc Nephrol 1999; 10: S385-S388
(check this in PDF content)
241
Kobayashi H, Shibata K, Fujie M et al. Identification of structural domains in inter-a-trypsin inhibitor involved in calcium oxalate crystallization. Kidney Int 1998; 53: 1727-1735
(check this in PDF content)
242
Marengo SR, Resnick MI, Yang L, Chung JY. Differential expression of urinary inter-alpha-trypsin inhibitor trimers and dimers in normal compare to active calcium oxalate stone forming men. J Urol 1998; 159 (5): 1444-1450
(check this in PDF content)
243
Evan AP, Bledsoe S, Worcester EM et al. Renal inter­ alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int 2007; 72 (12): 1503-1511
(check this in PDF content)
244
Suzuki M, Kobayashi H, Kageyama S et al. Excretion of bikunin and its fragments in the urine of patients with renal stones. J Urol 2001; 166 (1): 268-274
(check this in PDF content)
245
Moczydlowski E, Moss GW, Lucchesi KJ. Bovine pancreatic trypsin inhibitor as a probe of large conductance Ca(2+)-activated K+ channels at an internal site of interaction. Biochem Pharmacol 1992; 43: 21-28
(check this in PDF content)
246
Stapleton AM, Ryall RL. Crystal matrix protein­ getting blood out of a stone. Miner Electrolyte Metab 1994; 20 (6): 399-409
(check this in PDF content)
247
Stapleton AM, Simpson RJ, Ryall RL. Crystal matrix protein is related to human prothrombin. Biochem Biophys Res Commun 1993; 195 (3): 1199-1203
(check this in PDF content)
248
Suzuki K, Moriyama M, Nakajima C et al. Isolation and partial characterization of crystal matrix protein as a potent inhibitor of calcium oxalate crystal aggregation: evidence of activation peptide of human prothrombin. Urol Res 1994; 22 (1): 45-50
(check this in PDF content)
249
Stapleton AM, Ryall RL. Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br J Urol 1995; 75 (6): 712-719
(check this in PDF content)
250
Stapleton AM, Dawson CJ, Grover PK et al. Further evidence linking urolithiasis and blood coagulation: urinary prothrombin fragment 1 is present in stone matrix. Kidney Int 1996; 49 (3): 880-888
(check this in PDF content)
251
Grover PK, Thurgood LA, Ryall RL. Effect of urine fractionation on attachment of calcium oxalate crystals to renal epithelial cells: implications for studying renal calculogenesis. Am J Physiol Renal Physiol 2007; 292 (5): F1396-F1403
(check this in PDF content)
252
Atmani F, Glenton PA, Khan SR. Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects. Urol Res 1998; 26 (3): 201-207
(check this in PDF content)
253
Ryall RL. Glycosaminoglycans, proteins, and stone formation: adult themes and child’s play. Pediatr Nephrol 1996; 10 (5): 656-666
(check this in PDF content)
254
Ryall RL, Grover PK, Stapleton AM et al. The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci (Lond) 1995; 89 (5): 533-541
(check this in PDF content)
255
Grover PK, Ryall RL. Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. Eur J Biochem 1999; 263 (1): 50-56
(check this in PDF content)
256
Grover PK, Ryall RL. Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity. Clin Sci (Lond) 2002; 102 (4): 425-434
(check this in PDF content)
257
Walton RC, Kavanagh JP, Heywood BR, Rao PN. The association of different urinary proteins with calcium oxalate hydromorphs. Evidence for non-specific interactions. Biochim Biophys Acta 2005; 1723 (1-3): 175-183
(check this in PDF content)
258
Gul A, Rez P. Models for protein binding to calcium oxalate surfaces. Urol Res 2007; 35 (2): 63-71
(check this in PDF content)
259
Webber D, Rodgers AL, Sturrock ED. Synergism between urinary prothrombin fragment 1 and urine: a comparison of inhibitory activities in stone-prone and stone- free population groups. Clin Chem Lab Med 2002; 40 (9): 930­ 936
(check this in PDF content)
260
Webber D, Radcliffe CM, Royle L et al. Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation. FEBS J 2006; 273 (13): 3024-3037
(check this in PDF content)
261
Webber D, Rodgers AL, Sturrock ED. Glycosylation of prothrombin fragment 1 governs calcium oxalate crystal nucleation and aggregation, but not crystal growth. Urol Res 2007; 35 (6): 277-285
(check this in PDF content)
262
Buchholz NP, Kim DS, Grover PK at el. The effect of warfarin therapy on the charge properties of urinary prothrombin fragment 1 and crystallization of calcium oxalate in undiluted human urine. J Bone Miner Res 1999; 14 (6): 1003-1012
(check this in PDF content)
263
Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7 (2): 99-111
(check this in PDF content)
264
Stapleton AM, Timme TL, Ryall RL. Gene expression of pr othrombin in the human kidney and its potential relevance to kidney stone disease. Br J Urol 1998; 81 (5): 666­ 671
(check this in PDF content)
265
Grover PK, Miyazawa K, Coleman M et al. Renal prothrombin mRNA is significantly decreased in a hyperoxaluric rat model of nephrolithiasis. J Pathol 2006; 210 (3): 273-281
(check this in PDF content)
266
Hof M, Fleming GR, Fidler V. Time-resolved fluorescence study of a calcium-induced conformational change in prothrombin fragment 1. Proteins 1996; 24 (4): 485­ 494
(check this in PDF content)
267
Li L, Darden T, Hiskey R, Pedersen LG. Computational studies of human prothrombin fragment 1, the Gla domain of factor IX and several biological interesting mutants. Haemostasis 1996; 26 (1): 54-59 Поступила в редакцию 03.08.2009 г.
(check this in PDF content)